Australia markets closed

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
27.25+0.29 (+1.08%)
At close: 04:00PM EDT
27.25 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close26.96
Open27.04
Bid27.23 x 1100
Ask27.26 x 1800
Day's range24.53 - 27.45
52-week range12.01 - 46.16
Volume497,135
Avg. volume425,363
Market cap4.041B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Cerevel Therapeutics to Present at the Jefferies Healthcare Conference

    CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chairperson and chief executive officer Tony Coles, M.D. will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8 at 10:30 am ET. The live webcast of the fireside chat can be accessed on the investor relations section of the Cerevel Therapeutics website here. A rep

  • GlobeNewswire

    Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates

    On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022 Data for the darigabat Phase 2 proof-of-concept trial in focal epilepsy now expected mid-year 2023, revised from 2H 2022 $550.9M in cash, cash equivalents and marketable securities as of March 31, 2022; additional $37.5M from tavapadon risk-sharing arrangement received in April 2022 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Th

  • GlobeNewswire

    Cerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update on Tuesday, May 10, 2022

    CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2022 financial results on Tuesday, May 10, 2022, before the U.S. financial markets open. Management will host a conference call to discuss first quarter 2022 financial results and recent business updates on Tuesday, May 10, 2022 at 8:00 a.m. ET. To access the call, please